Literature DB >> 1681771

Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways.

I Erjefält1, C G Persson.   

Abstract

Inflammatory stimulus-induced luminal exudation of plasma proteins is potentially pathogenic in asthma. This study of plasma exudation into tracheobronchial airways examines antiexudative effects (potency and duration of action) of two beta 2-agonists in anesthetized guinea pigs. The exudative response to airway provocations with bradykinin 1.25 x 10(-4) M (5 nmol) was determined in different groups of animals 10, 300, 450, and 600 min, respectively, after the mucosa had been treated topically with salbutamol 10(-6) to 10(-4) M (0.1 to 10 nmol), formoterol 10(-9) to 10(-7) M (0.1 to 10 pmol), or saline (control). Exuded plasma in tracheal lavage liquids was calculated from their contents of the plasma tracer, 125I-albumin, given intravenously 10 min before provocation with bradykinin. Salbutamol (1 and 10 nmol) and formoterol (1 and 10 pmol) promptly inhibited the mucosal exudation (p less than 0.001). Propranolol, 0.1 nmol, reduced (p less than 0.01) the antiexudative effects of both drugs. Only formoterol (1 and 10 pmol) maintained its effect at 300 min, abating gradually at 450 and 600 min. In a group of sensitized guinea pigs, formoterol (1 and 10 pmol) was demonstrated to inhibit also allergen-induced luminal exudation of plasma (p less than 0.001). It is suggested that an antiexudative action may contribute to the long duration of formoterol's antiasthma effect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1681771     DOI: 10.1164/ajrccm/144.4.788

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  The use of the nose to study the inflammatory response of the respiratory tract.

Authors:  C G Persson; C Svensson; L Greiff; M Anderson; P Wollmer; U Alkner; I Erjefält
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

Review 2.  Long-acting beta2-agonists in asthma: not so SMART?

Authors:  Graeme P Currie; Daniel K C Lee; Brian J Lipworth
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro.

Authors:  R Anderson; C Feldman; A J Theron; G Ramafi; P J Cole; R Wilson
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

4.  Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs.

Authors:  Giuseppe Rossoni; Barbara Manfredi; Roberta Razzetti; Maurizio Civelli; Stefano Bongrani; Ferruccio Berti
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

5.  Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects.

Authors:  L Greiff; P Wollmer; M Andersson; C Svensson; C G Persson
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

6.  Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions.

Authors:  A Tachibana; M Kato; H Kimura; T Fujiu; M Suzuki; A Morikawa
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

7.  The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo.

Authors:  S R O'Donnell; G P Anderson
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

8.  Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung.

Authors:  C J Whelan; M Johnson; C J Vardey
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

9.  Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig.

Authors:  T Sakamoto; P J Barnes; K F Chung
Journal:  Agents Actions       Date:  1993-09

10.  Receptor-mediated enhancement of beta adrenergic drug activity by ascorbate in vitro and in vivo.

Authors:  Patrick F Dillon; Robert Root-Bernstein; N Edward Robinson; William M Abraham; Catherine Berney
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.